CSCs are characterized by a multidrug-resistant phenotype, because of the high levels of P-glycoprotein (Pgp), an ATP binding cassette (ABC) transporter that reduces the intracellular accumulation of drugs, including temozolomide [9, 10], the first-line therapy in GBM treatment. The gene discussed is ABCG2; the disease is glioblastoma.